

15 Nov 2016 | Opinion

About ARM

by Faraz Ali

The Alliance for Regenerative Medicine is partnering with representatives from other organizations engaged in multi-stakeholder initiatives to prepare the health care system for curative and/or regenerative medicines.

The Alliance for Regenerative Medicine is the largest single advocacy organization dedicated to the emerging field of regenerative medicine. ARM was established to support a dialog between the developers of transformational new therapies and policy makers at all levels, with the goal of increasing awareness about these new therapies and their potential benefits and costs, as well as generating and evaluating potential policy solutions to appropriately enable access for patients that address the needs of all key stakeholders.

ARM encourages a productive discussion on these critical topics with patients, public and private payers and other stakeholders as we work together to identify and promote solutions that will ensure potentially life-transforming technologies become widely accessible and adopted as and when their promise is realized.

ARM also partners with representatives from other organizations engaged in multi-stakeholder initiatives to prepare the health care system for curative and/or regenerative medicines. (See *Exhibit 1*.) These include the Biotechnology Innovation Organization (BIO), the International Society for Cellular Therapy (ISCT), the National Marrow Donor Program (NMDP), the NEW Drug Development ParadIGms (NEWDIGS) program at the Massachusetts Institute of Technology (MIT), the American and European Societies for Gene and Cell Therapy (ASGCT and ESGCT), the International Society for Stem Cell Research (ISSCR), and the Tissue Engineering and Regenerative Medicine International Society (TERMIS), among others.

Exhibit 1

Source:



Source: Alliance for Regenerative Medicine